Genetic Variants of ADAM9 As Potential Predictors for Biochemical Recurrence in Prostate Cancer Patients After Receiving a Radical Prostatectomy

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2024 Dec 4

PMID 39628685

Authors

Yung-Wei Lin

Yu-Ching Wen

Chia-Yen Lin

Chi-Hao Hsiao

Kuo-Hao Ho

Hsiang-Ching Huang

Lun-Ching Chang

Shian-Shiang Wang

Shun-Fa Yang

Ming-Hsien Chien

Affiliations

Soon will be listed here.

Abstract

A disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) functions as a membranous bridge, forming cell-cell and cell-matrix connections that regulate tumor aggressiveness in various cancer types, including prostate cancer (PCa). Elevated ADAM9 levels in PCa were identified as a prognostic marker for biochemical recurrence (BCR) in patients who had undergone a radical prostatectomy (RP). However, impacts of genetic variants of ADAM9 on clinicopathological development and BCR remain unclear. Herein, we recruited 702 patients with PCa to evaluate associations of single-nucleotide polymorphisms (SNPs) of ADAM9 with the risk of BCR and clinicopathological development. We genotyped four loci of ADAM9 SNPs located in the promoter and intron regions using a TaqMan allelic discrimination assay, including rs10105311 (C/T), rs7006414 (T/C), rs6474526 (T/G), and rs78451751 (T/C) in 702 Taiwanese PCa patients. Our results showed that the risk of postoperative BCR was 1.508-fold higher in patients carrying the T/C genotype in ADAM9 rs7006414 compared to those with the homozygous T/T genotype, a phenomenon more pronounced in younger PCa patients (aged ≤ 65 years). Furthermore, patients with at least one polymorphic G allele in ADAM9 rs6474526 had a 2.016-fold increased risk of developing an advanced clinical primary tumor stage, particularly in a subpopulation without BCR. Clinical observations from the Genotype-Tissue Expression (GTEx) database showed increased ADAM9 expression in whole blood tissues among individuals carrying the polymorphic C allele of rs7006414 and the G allele of rs6474526. Additionally, data from The Cancer Genome Atlas indicated that elevated ADAM9 levels were observed in PCa tissues compared to corresponding matched normal tissues. Our findings suggest that the rs7006414 and rs6474526 genetic variants of ADAM9 may influence ADAM9 expression and are associated with BCR and clinicopathological development in PCa patients after an RP.

References

Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T . SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011; 29(18):2565-73. PMC: 3138634. DOI: 10.1200/JCO.2010.31.2405. View

Allemailem K, Almatroudi A, Alrumaihi F, Almansour N, Aldakheel F, Rather R . Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. Am J Transl Res. 2021; 13(4):3868-3889. PMC: 8129253. View

Lin Y, Wen Y, Chu C, Tung M, Yang Y, Hua K . Stabilization of ADAM9 by N-α-acetyltransferase 10 protein contributes to promoting progression of androgen-independent prostate cancer. Cell Death Dis. 2020; 11(7):591. PMC: 7385149. DOI: 10.1038/s41419-020-02786-2. View

Hunt R, Sauna Z, Ambudkar S, Gottesman M, Kimchi-Sarfaty C . Silent (synonymous) SNPs: should we care about them?. Methods Mol Biol. 2009; 578:23-39. DOI: 10.1007/978-1-60327-411-1_2. View

Shiota M, Fujimoto N, Imada K, Yokomizo A, Itsumi M, Takeuchi A . Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7. J Natl Cancer Inst. 2016; 108(7). DOI: 10.1093/jnci/djw005. View

Koupparis A, Grummet J, Hurtado-Coll A, Bell R, Buchan N, Goldenberg S . Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. Can Urol Assoc J. 2011; 5(6):E156-61. PMC: 3235222. DOI: 10.5489/cuaj.10057. View

Wu H, Yang L, Chen L . The Diversity of Long Noncoding RNAs and Their Generation. Trends Genet. 2017; 33(8):540-552. DOI: 10.1016/j.tig.2017.05.004. View

Bo M, Ventura M, Marinello R, Capello S, Casetta G, Fabris F . Relationship between Prostatic Specific Antigen (PSA) and volume of the prostate in the Benign Prostatic Hyperplasia in the elderly. Crit Rev Oncol Hematol. 2003; 47(3):207-11. DOI: 10.1016/s1040-8428(03)00094-5. View

Chang A, Lin L, Chen Y, Chen P, Liu S, Tai H . The ADAM9/WISP-1 axis cooperates with osteoblasts to stimulate primary prostate tumor growth and metastasis. Int J Biol Sci. 2023; 19(3):760-771. PMC: 9909997. DOI: 10.7150/ijbs.77495. View

10.

Benafif S, Kote-Jarai Z, Eeles R . A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). Cancer Epidemiol Biomarkers Prev. 2018; 27(8):845-857. PMC: 6051932. DOI: 10.1158/1055-9965.EPI-16-1046. View

11.

Chan E . Next-generation sequencing methods: impact of sequencing accuracy on SNP discovery. Methods Mol Biol. 2009; 578:95-111. DOI: 10.1007/978-1-60327-411-1_5. View

12.

Cong L, Jia J . Promoter polymorphisms which regulate ADAM9 transcription are protective against sporadic Alzheimer's disease. Neurobiol Aging. 2009; 32(1):54-62. DOI: 10.1016/j.neurobiolaging.2009.01.001. View

13.

Lin Y, Wang S, Wen Y, Tung M, Lee L, Yang S . Genetic Variations of Melatonin Receptor Type 1A are Associated with the Clinicopathologic Development of Urothelial Cell Carcinoma. Int J Med Sci. 2017; 14(11):1130-1135. PMC: 5666544. DOI: 10.7150/ijms.20629. View

14.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

15.

Campbell T, Castro M, de Santiago I, Fletcher M, Halim S, Prathalingam R . FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness. Carcinogenesis. 2016; 37(8):741-750. PMC: 4967216. DOI: 10.1093/carcin/bgw065. View

16.

Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel S . Biochemical recurrence after radical prostatectomy: what does it mean?. Int Braz J Urol. 2017; 44(1):14-21. PMC: 5815528. DOI: 10.1590/S1677-5538.IBJU.2016.0656. View

17.

Fritzsche F, Jung M, Tolle A, Wild P, Hartmann A, Wassermann K . ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol. 2007; 54(5):1097-106. DOI: 10.1016/j.eururo.2007.11.034. View

18.

Cookson M, Aus G, Burnett A, Canby-Hagino E, DAmico A, Dmochowski R . Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in.... J Urol. 2007; 177(2):540-5. DOI: 10.1016/j.juro.2006.10.097. View

19.

Jaboin J, Hwang M, Lopater Z, Chen H, Ray G, Perez C . The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2010; 79(5):1330-5. PMC: 3782412. DOI: 10.1016/j.ijrobp.2010.01.013. View

20.

Josson S, Anderson C, Sung S, Johnstone P, Kubo H, Hsieh C . Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate. 2010; 71(3):232-40. PMC: 3174735. DOI: 10.1002/pros.21237. View